Mark Juckett

1.0k total citations
16 papers, 521 citations indexed

About

Mark Juckett is a scholar working on Hematology, Immunology and Molecular Biology. According to data from OpenAlex, Mark Juckett has authored 16 papers receiving a total of 521 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 7 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Mark Juckett's work include Acute Myeloid Leukemia Research (6 papers), Immune Cell Function and Interaction (4 papers) and Multiple Myeloma Research and Treatments (3 papers). Mark Juckett is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Immune Cell Function and Interaction (4 papers) and Multiple Myeloma Research and Treatments (3 papers). Mark Juckett collaborates with scholars based in United States, France and India. Mark Juckett's co-authors include Elizabeth H. Perry, Daniel J. Weisdorf, John F. DiPersio, Carolyn A. Keever-Taylor, William R. Drobyski, James T. Casper, Wenting Wu, Chung‐Che Chang, Arturo Loaiza‐Bonilla and Bal Kampalath and has published in prestigious journals such as Journal of Clinical Investigation, Blood and Transplantation.

In The Last Decade

Mark Juckett

15 papers receiving 505 citations

Peers

Mark Juckett

HEMAT

ONCOL

IMMUN

GENET

Dolores Caballero Spain

A. R. Zander Germany

Ghee Young Kwon South Korea

Hien K. Duong United States

P Anderlini United States

Rafael Martínez Spain

M. P. A. Lyttelton United Kingdom

Paulina Lange United States

F. Dreyfus France

Sue Corringham United States

Dolores Caballero Spain

Mark Juckett

305 ×1.2

HEMAT

107 ×0.6

123 ×0.8

ONCOL

77 ×0.6

IMMUN

124 ×1.0

GENET

Citations per year, relative to Mark Juckett Mark Juckett (= 1×) peers Dolores Caballero

Countries citing papers authored by Mark Juckett

Since Specialization

Citations

This map shows the geographic impact of Mark Juckett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Juckett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Juckett more than expected).

Fields of papers citing papers by Mark Juckett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Juckett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Juckett. The network helps show where Mark Juckett may publish in the future.

Co-authorship network of co-authors of Mark Juckett

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Juckett. A scholar is included among the top collaborators of Mark Juckett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Juckett. Mark Juckett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Malki, Monzr M. Al, Mark Juckett, Miguel‐Angel Perales, et al.. (2025). A Phase I, First in Human Open Label Study to Evaluate the Safety and Tolerability of TRX103 Cell Infusion in Subjects with Hematological Malignancies Undergoing HLA-Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT).. Transplantation and Cellular Therapy. 31(2). S291–S291.

Davis, Zachary, Frank Cichocki, Martin Felices, et al.. (2022). A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML. Blood. 140(Supplement 1). 10288–10289. 7 indexed citations

Westervelt, Peter, Partow Kebriaei, Mark Juckett, et al.. (2022). Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study. Blood. 140(Supplement 1). 2117–2119. 5 indexed citations

Kong, Guangyao, Mark Wunderlich, David T. Yang, et al.. (2014). Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. Journal of Clinical Investigation. 124(6). 2762–2773. 38 indexed citations

Zeidan, Amer M., Ju‐Whei Lee, Thomas Prébet, et al.. (2014). Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. British Journal of Haematology. 167(1). 62–68. 21 indexed citations

Costanzo, Erin S., et al.. (2012). Immune Responses Contribute to Depression, Fatigue, and Pain in Hematopoietic Stem Cell Transplant Recipients. Cancer Epidemiology Biomarkers & Prevention. 21(3). 565–566. 1 indexed citations

Cashen, Amanda F., Mark Juckett, Mark R. Litzow, et al.. (2011). Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Annals of Hematology. 91(1). 33–38. 53 indexed citations

Prébet, Thomas, Steven D. Gore, Zhuoxin Sun, et al.. (2010). Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Blood. 116(21). 601–601. 20 indexed citations

Schaefer, Élise, Arturo Loaiza‐Bonilla, Mark Juckett, et al.. (2009). A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 94(10). 1375–1382. 90 indexed citations

10.

Chang, Cheng‐Chang, Christopher Bredeson, Mark Juckett, Brent R. Logan, & Carolyn A. Keever-Taylor. (2003). Tumor load in patients with follicular lymphoma post stem cell transplantation may correlate with clinical course. Bone Marrow Transplantation. 32(3). 287–291. 10 indexed citations

11.

Keever-Taylor, Carolyn A., Christopher Bredeson, Fausto R. Loberiza, et al.. (2001). Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biology of Blood and Marrow Transplantation. 7(11). 620–630. 51 indexed citations

12.

Eshoa, Camellia, Sherrie L. Perkins, Bal Kampalath, et al.. (2001). Decreased CD10 Expression in Grade III and in Interfollicular Infiltrates of Follicular Lymphomas. American Journal of Clinical Pathology. 115(6). 862–867. 56 indexed citations

13.

Roza, Allan M., et al.. (2001). ADENOCARCINOMA ARISING IN A TRANSPLANTED PANCREAS. Transplantation. 72(6). 1156–1157. 20 indexed citations

14.

Juckett, Mark, Philip Rowlings, Martin J. Hessner, et al.. (1998). T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin’s lymphoma: clinical and molecular follow-up. Bone Marrow Transplantation. 21(9). 893–899. 47 indexed citations

15.

Kawanishi, Y, Jakob Passweg, William R. Drobyski, et al.. (1997). Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. Bone Marrow Transplantation. 19(11). 1069–1077. 41 indexed citations

16.

Juckett, Mark, et al.. (1991). Hemolytic uremic syndrome following bone marrow transplantation.. PubMed. 7(5). 405–9. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact